Effect of midazolam in autism spectrum disorder: A retrospective observational analysis
Authors' conclusion
Patients with autism spectrum disorder may be susceptible to premedication with midazolam; however, regular benzodiazepine administration may reduce the effect.
Study context
- Population
- Uncooperative patients receiving midazolam premedication before sevoflurane GA for dental treatment
- Participants
- 390 patients
- Exposure
- Autism spectrum disorder vs no autism spectrum disorder, effect of midazolam premedication
- Outcome
- Observer's Assessment of Alertness/Sedation score
- Follow-up
- 30 min after premedication
Methodological detailsordinal logistic regression, Data extracted from anesthesia and medical records, April 2017 to August 2018
- Ordinal logistic regression
- Data extracted from anesthesia and medical records, April 2017 to August 2018
Main finding
As reported in the abstract
Factors associated with Observer's Assessment of Alertness/Sedation score
Age, OR (95% CI 1.213-1.708), P < .001
1.437
Autism spectrum disorder, OR (95% CI 1.079-1.612), P = .007
1.318
Benzodiazepine medication, OR (95% CI 0.396-0.827), P = .002
0.574
Intramuscular route, OR (95% CI 1.137-1.924), P = .004
1.478
Observational data: associations, not effects.
Further findings
Correlation of sedation score with cooperation level
- During admission, Kendall τ (P < .001)
- −0.714
- During inhalation induction, Kendall τ (P < .001)
- −0.606
- Negative association
Original publication
Effect of midazolam in autism spectrum disorder: A retrospective observational analysis. Acta Anaesthesiol Scand. Published 15 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →